Literature DB >> 12930354

Engineered CD3 antibodies for immunosuppression.

L Renders, T Valerius.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12930354      PMCID： PMC1808799          DOI： 10.1046/j.1365-2249.2003.02227.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  29 in total

1.  Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection.

Authors:  P J Friend; G Hale; L Chatenoud; P Rebello; J Bradley; S Thiru; J M Phillips; H Waldmann
Journal:  Transplantation       Date:  1999-12-15       Impact factor: 4.939

Review 2.  Therapeutic approaches for transplantation.

Authors:  H Waldmann
Journal:  Curr Opin Immunol       Date:  2001-10       Impact factor: 7.486

3.  Molecular basis for immune complex recognition: a comparison of Fc-receptor structures.

Authors:  P Sondermann; J Kaiser; U Jacob
Journal:  J Mol Biol       Date:  2001-06-08       Impact factor: 5.469

4.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

Authors:  Kevan C Herold; William Hagopian; Julie A Auger; Ena Poumian-Ruiz; Lesley Taylor; David Donaldson; Stephen E Gitelman; David M Harlan; Danlin Xu; Robert A Zivin; Jeffrey A Bluestone
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

5.  High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

Authors:  R L Shields; A K Namenuk; K Hong; Y G Meng; J Rae; J Briggs; D Xie; J Lai; A Stadlen; B Li; J A Fox; L G Presta
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

Review 6.  CD3-specific antibody-induced active tolerance: from bench to bedside.

Authors:  Lucienne Chatenoud
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

7.  Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors.

Authors:  D J Norman; F Vincenti; A M de Mattos; J M Barry; D J Levitt; N I Wedel; M Maia; S E Light
Journal:  Transplantation       Date:  2000-12-27       Impact factor: 4.939

Review 8.  IgA antibodies for cancer therapy.

Authors:  M Dechant; T Valerius
Journal:  Crit Rev Oncol Hematol       Date:  2001 Jul-Aug       Impact factor: 6.312

9.  Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.

Authors:  Tammy O Utset; Julie A Auger; Donna Peace; Robert A Zivin; Danlin Xu; Linda Jolliffe; Maria-Luisa Alegre; Jeffrey A Bluestone; Marcus R Clark
Journal:  J Rheumatol       Date:  2002-09       Impact factor: 4.666

10.  Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

Authors:  Kevan C Herold; Joshua B Burton; Fleur Francois; Ena Poumian-Ruiz; Mariela Glandt; Jeffrey A Bluestone
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808
View more
  3 in total

1.  Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial.

Authors:  Gadi Lalazar; Meir Mizrahi; Ilit Turgeman; Tomer Adar; Ami Ben Ya'acov; Yehudit Shabat; Assy Nimer; Nila Hemed; Lidya Zolotarovya; Yoav Lichtenstein; Nadya Lisovoder; Sarit Samira; Itamar Shalit; Ronald Ellis; Yaron Ilan
Journal:  J Clin Immunol       Date:  2015-04-17       Impact factor: 8.317

2.  Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance.

Authors:  Hyunwon Yang; Yun-Hee Youm; Bolormaa Vandanmagsar; Anthony Ravussin; Jeffrey M Gimble; Frank Greenway; Jacqueline M Stephens; Randall L Mynatt; Vishwa Deep Dixit
Journal:  J Immunol       Date:  2010-06-25       Impact factor: 5.422

3.  Muronomab-CD3 for pediatric acute myocarditis.

Authors:  Gregory Perens; Daniel S Levi; Juan Carlos Alejos; Glenn T Wetzel
Journal:  Pediatr Cardiol       Date:  2006-12-07       Impact factor: 1.655
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.